Medical Services

Boston Scientific Feels Guidant's Pain

 

Boston Scientific (BSX) is recalling a group of pacemakers and defibrillators, all of which were made by the business that used to be the stand-alone company Guidant, because the devices could fail.

The recall covers the Insignia and Nexus pacemakers, Contak Renewal TR/TR2 cardiac resynchronization pacemakers and Ventak Prizm 2, Vitality and Vitality 2 implantable cardioverter defibrillators. The products are made by Boston Scientific's cardiac rhythm management group that was formerly part of Guidant.

Boston Scientific, based in Natick, Mass., said it had recently identified a low-voltage capacitor in the devices that isn't performing properly. A capacitor is an electrical-charge storage component.

Some capacitors, if not working properly, could lead to a malfunction. To date, five defects have been confirmed, but no deaths have been reported. Roughly 27,200 of the devices have been implanted.

Product recalls are nothing new to Guidant. Boston Scientific acquired the company on April 21 after prevailing in a bidding war with Johnson & Johnson (JNJ). J&J had originally planned to buy Guidant, but balked last year after the company recalled thousands of heart devices over several months.

Ultimately, J&J said it would still finish the deal, but at a lower price. However, Boston Scientific emerged with a higher bid, and after a series of amended proposals ended up with Guidant.

Shares of Boston Scientific were trading at a 52-week low, dropping $1.33, or 7.3%, to $16.93. The stock's lowest close in the past year is $18.06, and its high is $29.35. Volume was more than twice as heavy as normal.

>To order reprints of this article, click here: Reprints

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,419.86 1,313.32 2,837.36 16.25
Oil *
103.00
DOWN
160.83
DOWN
19.10
DOWN
33.63
DOWN
1.06
10 Yr
1.62%
SPDR Gold
151.91
-1.28%
-1.43%
-1.17%
-6.12%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet